Drug Discov Ther. 2016;10(2):109-113. (DOI: 10.5582/ddt.2016.01010)
Inhibition of PA endonuclease activity of influenza virus RNA polymerase by Kampo medicines.
Shirayama R, Shoji M, Sriwilaijaroen N, Hiramatsu H, Suzuki Y, Kuzuhara T
To find a novel influenza inhibitor targeting the endonuclease activity of influenza A virus polymerase acidic protein (PA), which is essential for the acquisition of primers for viral mRNA transcription, seven Kampo extracts were tested in vitro for their ability to inhibit endonuclease activity of the recombinant PA protein that was expressed and purified from Escherichia coli. The Kampo medicines Kakkonto, Shosaikoto, Saikokeishito, Keishito, Maobushisaishinto, and Maoto, but not Chikujountanto, inhibited PA endonuclease activity in a dose-dependent manner. Our results indicate that Kampo medicines are good sources providing a structural lead for optimization of an influenza endonuclease inhibitor.
Full Text: 
